NASDAQ:SGYP

Synergy Pharmaceuticals Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.

Add

Compare

Today's Range N/A

50-Day Range

$0.01

▼

$0.03

52-Week Range N/A

VolumeN/A

Average Volume6.08 million shs

Market Capitalization$7.44 million

P/E RatioN/A

Dividend YieldN/A

Beta4.94

Receive SGYP News and Ratings via Email

Sign-up to receive the latest news and ratings for Synergy Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

About Synergy Pharmaceuticals

Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders. Its lead product is plecanatide, a novel uroguanylin based gastrointestinal platform that is traded under the TRULANCE name for the treatment of chronic idiopathic constipation and irritable bowel syndrome. The company also develops dolcanatide to treat mild-to-moderate ulcerative colitis. It has a licensing agreement with Cipher Pharmaceuticals Inc. to develop, market, distribute, and sell TRULANCE in Canada. Synergy Pharmaceuticals Inc. is headquartered in New York, New York. On December 12, 2018, Synergy Pharmaceuticals Inc. along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.

News for Synergy Pharmaceuticals Inc.
October 21, 2020 | markets.businessinsider.com

Synergy Pharmaceuticals Inc. - Profile
August 20, 2020 | markets.businessinsider.com

Synergy Pharmaceuticals (SGYP) Surges: Stock Moves 12.1% Higher
July 23, 2020 | sg.finance.yahoo.com

CORRECTING and REPLACING Synergy Pharmaceuticals Reports Second Quarter 2018 Financial Results and Business Update
May 23, 2020 | www.bloomberg.com

Synergy Pharmaceuticals Strengthens Coverage for TRULANCE® (plecanatide) with Key New Market Access Wins
May 23, 2020 | www.bloomberg.com

Identify IBS Treatment Market Regional Growth Drivers Electrifying Development Pace
March 18, 2020 | www.marketwatch.com

FINAL DEADLINE: Bronstein, Gewirtz & Grossman, LLC - UXIN, SGYP & MHLD
April 12, 2019 | finance.yahoo.com

DEADLINE FRIDAY REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Synergy Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
April 10, 2019 | finance.yahoo.com

DEADLINE FRIDAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Synergy Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
April 9, 2019 | finance.yahoo.com

SGYP & MHLD - Class Action Bronstein, Gewirtz & Grossman, LLC
April 9, 2019 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:SGYP
Previous Symbol
CUSIP87163930
CIK1347613
Webwww.synergypharma.com
Phone212-297-0020
EmployeesN/A
Year FoundedN/A

Sales & Book Value

Annual Sales$16.82 million
Price / Sales0.00
Cash FlowN/A
Price / Cash FlowN/A
Book Value($0.02) per share
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)($1.02)
Net Income$-224,330,000.00
Net Margins-332.11%
Return on EquityN/A
Return on Assets-118.14%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares248,040,000
Market Cap$7.44 million
Next Earnings DateN/A
OptionableOptionable

MarketRank^™

Overall MarketRank^™

0.99 out of 5 stars

Medical Sector

1583rd out of 2,220 stocks

Pharmaceutical Preparations Industry

696th out of 869 stocks

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Synergy Pharmaceuticals.

4.9 Community Rank

Outperform Votes
Synergy Pharmaceuticals has received 755 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Synergy Pharmaceuticals has received 256 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Synergy Pharmaceuticals has received 74.68% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Synergy Pharmaceuticals and other stocks. Vote “Outperform” if you believe SGYP will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SGYP will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Synergy Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Synergy Pharmaceuticals does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Synergy Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.80% of the stock of Synergy Pharmaceuticals is held by insiders.
Percentage Held by Institutions
Only 28.47% of the stock of Synergy Pharmaceuticals is held by institutions.

0.0 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Synergy Pharmaceuticals is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Synergy Pharmaceuticals is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Synergy Pharmaceuticals (NASDAQ:SGYP) Frequently Asked Questions

What stocks does MarketBeat like better than Synergy Pharmaceuticals?

Wall Street analysts have given Synergy Pharmaceuticals a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Synergy Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Synergy Pharmaceuticals' earnings last quarter?

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) released its quarterly earnings data on Thursday, November, 8th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by $0.01. The biopharmaceutical company earned $11.11 million during the quarter, compared to analysts' expectations of $15.65 million.
View Synergy Pharmaceuticals' earnings history.

Who are Synergy Pharmaceuticals' key executives?

Synergy Pharmaceuticals' management team includes the following people:

Mr. Troy Hamilton Pharm.D., CEO & Director (Age 47)
Mr. Gary G. Gemignani, Exec. VP & CFO (Age 54)
Gem Gokmen Hopkins, VP of Investor Relations and Corp. Communications
Ms. Pamela Cebulski, Sr. VP of Marketing
Ms. Marianne Jackson, Sr. VP of Sales & Market Access

Who are some of Synergy Pharmaceuticals' key competitors?

Some companies that are related to Synergy Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), Exact Sciences (EXAS), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Novavax (NVAX), Neurocrine Biosciences (NBIX) and United Therapeutics (UTHR).
View all of SGYP's competitors.

What other stocks do shareholders of Synergy Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Synergy Pharmaceuticals investors own include Novavax (NVAX), Immunomedics (IMMU), Progenics Pharmaceuticals (PGNX), Inovio Pharmaceuticals (INO), ACADIA Pharmaceuticals (ACAD), Cara Therapeutics (CARA), OPKO Health (OPK), Gilead Sciences (GILD), Exelixis (EXEL) and (SLS).

What is Synergy Pharmaceuticals' stock symbol?

Synergy Pharmaceuticals trades on the NASDAQ under the ticker symbol "SGYP."

How much money does Synergy Pharmaceuticals make?

Synergy Pharmaceuticals has a market capitalization of $0.00 and generates $16.82 million in revenue each year. The biopharmaceutical company earns $-224,330,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis.

What is Synergy Pharmaceuticals' official website?

The official website for Synergy Pharmaceuticals is www.synergypharma.com.

Where are Synergy Pharmaceuticals' headquarters?

Synergy Pharmaceuticals is headquartered at 420 LEXINGTON AVENUE SUITE 2012, NEW YORK NY, 10170.

How can I contact Synergy Pharmaceuticals?

Synergy Pharmaceuticals' mailing address is 420 LEXINGTON AVENUE SUITE 2012, NEW YORK NY, 10170. The biopharmaceutical company can be reached via phone at 212-297-0020 or via email at [email protected]

This page was last updated on 8/1/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Synergy Pharmaceuticals Stock Forecast, Price & News

About Synergy Pharmaceuticals

Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

MarketRank™

Overall MarketRank™

0.0 Analyst's Opinion

4.9 Community Rank

Outperform Votes

Underperform Votes

Community Sentiment

0.0 Dividend Strength

0.0 Company Ownership

0.0 Earnings and Valuation

Synergy Pharmaceuticals (NASDAQ:SGYP) Frequently Asked Questions

What stocks does MarketBeat like better than Synergy Pharmaceuticals?

How were Synergy Pharmaceuticals' earnings last quarter?

Who are Synergy Pharmaceuticals' key executives?

Who are some of Synergy Pharmaceuticals' key competitors?

What other stocks do shareholders of Synergy Pharmaceuticals own?

What is Synergy Pharmaceuticals' stock symbol?

How much money does Synergy Pharmaceuticals make?

What is Synergy Pharmaceuticals' official website?

Where are Synergy Pharmaceuticals' headquarters?

How can I contact Synergy Pharmaceuticals?

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources

MarketRank^™

Overall MarketRank^™